Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- 60% of Pharmacies Claim Premiums for Generics Dispensing System: NPhA Survey
December 20, 2010
- Ain Pharmaciez to Accelerate Development of Medical Malls
December 20, 2010
- Kyowa Kirin Announces Positive Japanese PII Results on KW-0761
December 20, 2010
- 2-Week Limit on Prescription Period Lifted for ARB/CCB Combination Drugs
December 20, 2010
- Astellas Enters into Strategic Equity Deal with Cytori
December 20, 2010
- Favorable Results for KW-0761 Also in US PI/PII Trial
December 20, 2010
- JMA Calls on Korosho to Reconsider Permission of Long-Term Prescriptions
December 20, 2010
- Kyowa Kirin Terminates License Agreement with LivTech for LIV-1205
December 20, 2010
- Favorable Long-Term PIII Results Published for Collategene: AnGes MG
December 20, 2010
- Revolade Benefits Patients with Intractable ITP: Prof. Ikeda
December 20, 2010
- Daiichi Sankyo Subsidiary Luitpold Acquires ROXRO PHARMA
December 20, 2010
- Daiichi Sankyo Completes Enrollment for Edoxaban PIII Trial
December 20, 2010
- Norspan Useful in Getting Doctors Conversant with Opioids: Prof. Ogawa
December 20, 2010
- Sanofi-aventis Extends Tender Offer for Genzyme Shares
December 20, 2010
- Novel Anticoagulants Gaining Popularity: Dr Yamashita
December 20, 2010
- Fixed-Dose Combination Eye Drops Improve Compliance: Dr Araie
December 20, 2010
- Mediscience to Acquire CRO Business from Tokyo Clinical CRO
December 20, 2010
- Industry Support Essential for iPS Cell Drug Discovery: Prof. Yamanaka
December 20, 2010
- NCGM Compiles Manual for Selection of Antidiabetic Drugs for GPs
December 20, 2010
- MTPC Takes Confidence-Building Measures
December 20, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…